Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag to prevent chemoradiotherapy-induced thrombocytopenia in limited-stage small cell lung cancer
ChiCTR2600118519Phase 4Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of hetrombopag in Thrombocytopenia and small cell lung cancer (SCLC) (4 arms), sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: Incidence of grade ≥3 chemotherapy-induced thrombocytopenia (CTIT) during the treatment period. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
hetrombopag
03
Conditions
Thrombocytopeniasmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2600118519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118519.